Table 5: COMPANION Results: Primary and Secondary Endpoints^*.

Endpoint (12-month rate)	Device	Absolute Benefit, %	Hazard ratio (95% CI)	P	NNT†
Primary (Combined) Endpoint
Death or hospitalization, any cause	BiV †	12	0.81 (0.69–0.96)	.015	8
	BiV& ICD†	12	0.80 (0.68–0.95)	.010	8
Secondary Endpoint
Death from any cause	BiV	4	0.76 (0.58–1.01)	.06	25
	BiV & ICD	7	0.64 (0.48–0.86)	.004	14
Death from or hospitalization for cardiovascular causes	BiV	15	0.75 (0.63–0.90)	.002	7
	BiV & ICD	16	0.72 (0.60–0.86)	< .001	6
Death from or hospitalization for HF	BiV	14	0.66 (0.53–0.87)	.002	7
	BiV & ICD	16	0.60 (0.49–0.75)	< .001	6

^†BiV refers to biventricular pacemaker; ICD, implantable cardioverter defibrillator; NNT, number needed to treat.

^*From Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine 2004; 350(21):2140-2150 (9)